Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003671 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
A Phase 2 study of Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 20
- Study locations
NCT00003671: Completed Phase 2 study of Leukemia, sponsored by Children's Oncology Group.
NCT00003671 is a Phase 2 study of Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 59 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003671, a Phase 2 study of Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have newly diagnosed acute lymphocytic leukemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Study Locations (20)
California
- Lucile Packard Children's Hospital at Stanford - Palo Alto
- Sutter Cancer Center - Sacramento
- Kaiser Permanente-Southern California Permanente Medical Group - San Diego
- Naval Medical Center - San Diego - San Diego
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
Florida
- Nemours Children's Clinic - Jacksonville
- Sylvester Cancer Center, University of Miami - Miami
- Baptist Hospital of Miami - Miami
- Walt Disney Memorial Cancer Institute - Orlando
- St. Mary's Hospital - West Palm Beach
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- Children's Memorial Hospital, Chicago - Chicago
- Christ Hospital - Oak Lawn
- Saint Jude Midwest Affiliate - Peoria
Arizona
- Arizona Cancer Center - Tucson
Georgia
- Emory University Hospital - Atlanta - Atlanta
Hawaii
- Tripler Army Medical Center - Honolulu
Kansas
- Via Christi Regional Medical Center-Saint Francis Campus - Wichita
Louisiana
- Tulane University School of Medicine - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 1998-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
What the finished NCT00003671 record still lists
NCT00003671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003671 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00003671 about?
NCT00003671 is a clinical study titled "Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have newly diagno...
What is the current status of trial NCT00003671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 1998-12. Estimated completion is 2009-02.
What conditions does trial NCT00003671 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00003671?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003671?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003671 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003671's enrollment target sits among peer trials
59 103rd of 233 higher than 130 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia